New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BMY;STRA;JNJ;IQNT;HES;VNO;NKTR;JCP;CAT;PBR;VRTX;KRC;GRMN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
May 12, 2015
15:32 EDTVRTXFDA panel inconclusive on if Lumacaftor contributes to Orkambi effectiveness
Subscribe for More Information
12:37 EDTSTRAFor-profit education stocks slide after SEC charges ITT with fraud
Subscribe for More Information
11:37 EDTJCPStocks with call strike movement; TWTR JCP
Subscribe for More Information
10:23 EDTVRTXVertex shares halted while FDA panel meeting takes place
07:58 EDTVRTXFDA Pulmonary-Allergy Drugs Advisory Committee to hold a meeting
Subscribe for More Information
May 11, 2015
17:58 EDTJNJJ&J's Janssen gets complete response letter regarding sNDA for Invega Sustenna
Subscribe for More Information
16:00 EDTJCPOptions Update; May 11, 2015
Subscribe for More Information
10:14 EDTCATAnalyst says buy Caterpillar, Joy Global before mining bottoms
The shares of Joy Global (JOY) and Caterpillar (CAT) are climbing after research firm Baird analyst Mircea Dobre upgraded both names, citing a potential bottom in commodity prices. Both companies develop mining equipment. WHAT'S NEW: In a note to investors earlier today, Baird's Dobre upgraded Joy Global and Caterpillar to Outperform from Market Perform. There are signs that the worst of the downturn in commodity prices may have passed, the analyst stated. Additionally, the shares of both Caterpillar and Joy Global historically bottom three to five quarters before mining equipment shipments rebound, according to Dobre. Consequently, investors who wait for evidence of a turnaround in the companies' mining equipment bookings may be late to the party, the analyst warned. Both stocks have now underperformed the market by amounts that are similar to their worst underperfomance during the early 1980s commodity bust, according to Dobre, who raised the price target on Caterpillar to $101 from $80 and on Joy Global to $62 from $45. PRICE ACTION: In early trading, Joy Global climbed nearly 4% to $43.64 and Caterpillar rose 1.5% to $88.60.
09:59 EDTCATOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alcatel-Lucent (ALU) upgraded to Outperform from Neutral at Exane BNP Paribas... Caterpillar (CAT) upgraded to Outperform at Baird... Cisco (CSCO) upgraded to Outperform with $36 target at Pacific Crest... Evolution Petroleum (EPM) upgraded to Outperform from Market Perform at Northland... Hecla Mining (HL) upgraded on hedging discipline at Roth Capital... Joy Global (JOY) upgraded to Outperform from Neutral at Baird... Monster Beverage (MNST) upgraded to Buy from Neutral at Citigroup... Nokia (NOK) upgraded to Outperform from Neutral at Exane BNP Paribas... On Deck Capital (ONDK) upgraded to Neutral from Sell at Sterne Agee CRT... Royal Caribbean (RCL) upgraded to Outperform from Neutral at Wedbush... SMC (SMECF) upgraded to Buy from Neutral at Goldman... Sally Beauty (SBH) upgraded to Outperform from Market Perform at Raymond James... Southwestern Energy (SWN) upgraded to Overweight from Equal Weight at Barclays... Sprouts Farmers Markets (SFM) upgraded to Outperform at BMO Capital... Suburban Propane (SPH) upgraded on positive outlook at Stifel... Suffolk Bancorp (SUBK) upgraded to Outperform from Market Perform at Keefe Bruyette... Syngenta (SYT) upgraded to Buy from Neutral at UBS... Triumph Group (TGI) upgraded to Outperform from Sector Perform at RBC Capital... United Natural Foods (UNFI) upgraded to Overweight from Equal Weight at Stephens... Web.com (WWWW) upgraded to Buy from Hold at Deutsche Bank... Zillow Group (Z) upgraded to Buy from Neutral at SunTrust.
09:02 EDTCATCaterpillar upgraded to Outperform at Baird
As reported previously, Baird upgraded Caterpillar to Outperform from Neutral as the firm noted the stock's meaningful underperformance over the past four years and its history of having never underperformed the broader market for five consecutive years. Baird raised its price target to $101 from $80 on Caterpillar shares.
07:40 EDTVRTXFocus on Vertex will shift to pricing after Orkambi FDA meeting, WSJ says
An FDA advisory committee that meets Tuesday to decide whether to recommend approval of Vertexís Orkambi will be closely watched by health insurers and pharmacy-benefit managers concerned that the experimental cystic-fibrosis drug will be high-priced, said The Wall Street Journal. Vertex hasnít announced a price, but analyst at JPMorgan predict the drug will have a wholesale price of about $287,000 annually per patient. Publicly traded PBM owners include Catamaran (CTRX), which is being acquired by UnitedHealth (UNH), CVS Health (CVS) and Express Scripts (ESRX). Reference Link
06:23 EDTCATCaterpillar upgraded to Outperform from Neutral at Baird
May 10, 2015
19:25 EDTJNJCourt rejects claim that drugmakers misled opiate patients, Bloomberg says
Subscribe for More Information
17:13 EDTPBRPetrobras seesk $152M in graft lawsuit, WSJ says
Subscribe for More Information
14:05 EDTJNJJohnson & Johnson shares may deliver double-digit returns, Barron's says
Subscribe for More Information
May 8, 2015
14:13 EDTVRTXOrkambi questions may make reimbursement talks harder, says Evercore ISI
Subscribe for More Information
10:59 EDTJCPJ.C. Penney May volatility elevated into Q1 and outlook
J.C. Penney May call option implied volatility is at 84, June is at 52, August is at 47, November is at 44; compared to its 90-week average of 50, suggesting large near term price movement into the expected release of Q1 results on May 15.
10:10 EDTVRTXPiper confident in Vertex getting positive panel vote for Orkambi
Piper Jaffray said the briefing documents posted for next Tuesday's advisory committee meeting on Vertex's Orkambi combo drug did not raise any new or surprise safety concerns and that the efficacy concerns raised do not "hold much water" when compared to the unmet clinic benefit of the drug. The firm said it remains confident in a positive panel vote and approval of the drug by the May 5 PDUFA date and reiterate kits Overweight rating and $146 price target on Vertex shares.
09:28 EDTVRTXOn The Fly: Pre-market Movers
Subscribe for More Information
08:12 EDTVRTXFDA staff question if Vertex CF drug combo adds benefit over ivacaftor alone
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use